Cheng-Long Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2937022/publications.pdf

Version: 2024-02-01

933447 888059 18 440 10 17 citations g-index h-index papers 18 18 18 746 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson's models. Neurochemistry International, 2022, 155, 105297.	3.8	18
2	Delineating the Role of Mitophagy Inducers for Alzheimer Disease Patients., 2021, 12, 852.		9
3	NAD+ in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo. Frontiers in Cell and Developmental Biology, 2021, 9, 668491.	3.7	17
4	The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review. Drug Design, Development and Therapy, 2020, Volume 14, 845-854.	4.3	3
5	Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats. Frontiers in Pharmacology, 2019, 10, 660.	3.5	7
6	Striatal overexpression of \hat{l}^2 -arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats. Neurochemistry International, 2019, 131, 104543.	3.8	8
7	β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson's rats. Aging, 2019, 11, 12315-12327.	3.1	10
8	Neuroprotective effects of N-acetyl cysteine on primary hippocampus neurons against hydrogen peroxide-induced injury are mediated via inhibition of mitogen-activated protein kinases signal transduction and antioxidative action. Molecular Medicine Reports, 2018, 17, 6647-6654.	2.4	6
9	Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Aging Neuroscience, 2018, 10, 262.	3.4	17
10	An Overview of Meta-Analyses of Endovascular Bridging Therapies for Acute Ischemic Stroke. BioMed Research International, 2018, 2018, 1-12.	1.9	6
11	Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. BMC Neurology, 2018, 18, 4.	1.8	99
12	Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats. Biomedicine and Pharmacotherapy, 2018, 107, 769-776.	5.6	14
13	The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurological Sciences, 2017, 38, 215-224.	1.9	76
14	Current Experimental Studies of Gene Therapy in Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 126.	3.4	12
15	A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo. Frontiers in Neurology, 2017, 8, 702.	2.4	9
16	Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review. BMC Complementary and Alternative Medicine, 2017, 17, 412.	3.7	82
17	Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress. Molecular Medicine Reports, 2017, 17, 1118-1124.	2.4	13
18	Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple-treatments meta-analysas of randomized controlled trials. Scientific Reports, 2016, 6, 25285.	3.3	34